Chuck Dukas
OCS 2025 Master of Ceremonies and Host
Download Bio
Download Presentation
Evaluation Card
LaBarbera
Nangia
Michael Mauro, MD
Sandra E. Kurtin, PhD, ANP-BC, AOCN, FAPO, graduated from the University of Arizona with a Bachelor of Science in Nursing with high distinction, a Master of Science in Oncology Nursing, post-graduate certification in both Geriatric and Adult Practice, and a PhD in Nursing. Her research focus is on heath
technology engagement, communicative health literacy, and health self-management among older adult cancer survivors. She is currently employed as a hematology/oncology nurse practitioner at the University of Arizona Cancer Center and serves as Assistant Professor of Clinical Medicine and Adjunct Clinical Assistant Professor of Nursing at the University of Arizona. Dr. Kurtin has 34 years of oncology nursing experience.
Learning Objectives:
- Review the clinical features of myelofibrosis, including risk stratification,
indicators of disease prognosis, and symptom burden
- Identify the expected outcomes and therapeutic goals associated with JAK
inhibitor treatment in myelofibrosis care
- Develop individualized strategies to reduce treatment toxicity and enhance
treatment adherence for patients with myelofibrosis
- Educate patients about the purpose of JAK inhibitors, potential side effects,
adherence to medication schedules, and the importance of regular monitoring
and follow-up appointments
Clara Beaver, DNP, RN, AOCNS, ACNS, BC
Beth Marie (Trebisky) Faiman PHD, RN, MSN, ANP-BC, BMTCN, AOCN, FAAN, FAPO
Nurse Practitioner, Department of Hematology and Medical Oncology Clinical member of the Case Comprehensive Cancer Center (Case CCC) under the Cancer Prevention, Control and Population (CPC) Research Program
Taussig Cancer Institute, Cleveland Clinic
Kimberly Halla, MSN, FNP-C
PRESENTERS
Click on each link below for a printable file.
Sandra E. Kurtin, PhD, ANP-BC, AOCN, FAPO, graduated from the University of Arizona with a Bachelor of Science in Nursing with high distinction, a Master of Science in Oncology Nursing, post-graduate certification in both Geriatric and Adult Practice, and a PhD in Nursing. Her research focus is on heath
technology engagement, communicative health literacy, and health self-management among older adult cancer survivors. She is currently employed as a hematology/oncology nurse practitioner at the University of Arizona Cancer Center and serves as Assistant Professor of Clinical Medicine and Adjunct Clinical Assistant Professor of Nursing at the University of Arizona. Dr. Kurtin has 34 years of oncology nursing experience.
Learning Objectives:
- Review the clinical features of myelofibrosis, including risk stratification,
indicators of disease prognosis, and symptom burden
- Identify the expected outcomes and therapeutic goals associated with JAK
inhibitor treatment in myelofibrosis care
- Develop individualized strategies to reduce treatment toxicity and enhance
treatment adherence for patients with myelofibrosis
- Educate patients about the purpose of JAK inhibitors, potential side effects,
adherence to medication schedules, and the importance of regular monitoring
and follow-up appointments
Sandra E. Kurtin, PhD, ANP-BC, AOCN, FAPO
J. Randolph Hech, MD
Dr. Faiman has become an exemplary leader in bringing critical knowledge in cancer nursing to clinical providers- locally, nationally and internationally. She demonstrates enthusiasm for continuous learning by conducting
innovative research, and has demonstrated the importance of using and integrating new medical knowledge within nursing practices. As an advanced practice nurse at the Cleveland Clinic, she led institutional quality initiatives to
lessen chemotherapy wait times for cancer patients. Dr. Faiman received her Bachelor of Science degree from Ursuline Academy in 1996, a Master of Science in nursing at Kent State University in Ohio in 2002, and a PhD in clinical research and nursing from Case Western Reserve University in 2014. A founding member of the International Myeloma Foundation Nurse Leadership Board since 2006, she also successfully lobbied to enhance nurse-prescribing privileges that year. In 2014, she co-developed nurse-led consult clinics to expedite diagnosis and
management of thrombosis in cancer patients, and plasma cell disorders. Faiman is a clinical member of the Case Comprehensive Cancer Center (Case CCC) under the Cancer Prevention, Control and Population (CPC) Research Program.
Faiman is currently an adult nurse practitioner in the Department of Hematology/Oncology at the Cleveland Clinic in Ohio. She has edited several books and authored many chapters and research papers, and led the development of International Myeloma management guidelines, including Editor of the 3rd Edition of the Multiple Myeloma Textbook for Nurses by ONS publishing company (2021), and the first Blood and Marrow Certification Manual for Nurses (2017). Faiman influenced cancer care practice by presenting at numerous international and US national conferences, and served as lecture chair at many of them. In 2013, Dr. Faiman served as co-chair of the 1st Nursing
Symposium at the International Myeloma Workshop in Kyoto, Japan and subsequent conferences, which includes the 6th nursing symposium in Los Angeles in 2022. Her scholarly publications and presentations are highly cited by
peers and colleagues. She has been invited Chair and participant in over 110 live and virtual programs over the last 5 years.
Faiman is the recipient of numerous awards and accolades. In 2023, Faiman was given the NP/PA Educator of Distinction Award in Multiple Myeloma. In 2022, Faiman was named the Top NP in Hematology/Oncology awarded by POCN; and inducted as an inaugural Fellow of Advanced Practice in Oncology (FAPO) awarded by the Advanced Practitioner Society for Hematology and Oncology (APSHO). Faiman is a Distinguished Fellow in the American Academy of Nursing (FAAN) and held an appointment on the American Board of Internal Medicine
Hematology maintenance of certification committee. She received awards from 2013 Oncology Nursing Society awards for Medical excellence and Patient Education; as well as the Case Western Reserve University Dean's Legacy Award for Outstanding Doctor of Philosophy studies. Dr. Faiman was previously Editor-in-Chief of The Oncology Nurse NP/PA and section editor for American Society of Hematology Clinical News. She currently serves as Editor-in-Chief of Journal of the Advanced Practitioner in Oncology (JADPRO), the official publication of
APSHO. Dr. Faiman demonstrates energy for advancing cancer care and immerses herself in national and international programs, services and leadership work within myeloma communities.
Julie LaBarbera is a Nurse Practitioner with 20 years in Oncology Nursing. She currently works at University of California Los Angeles and specializes in breast cancer. She is passionate about improving the quality of life for patients undergoing treatment of breast cancer while improving longevity and
treatment outcomes. In her free time, she enjoys spending time her family and pets, cooking, hiking, and reading.
Dr. J. Randolph Hecht is a Professor of Clinical Medicine at the David Geffen School of Medicine at UCLA School of Medicine. He holds the Carol and Saul Rosenzweig Chair for Cancer Therapies Development and is the Director of the UCLA Gastrointestinal Oncology Program. As an internationally known clinical
and translational researcher in the field of gastrointestinal cancers, Dr. Hecht has led and is currently directing small trials with new molecules as well as large international randomized Phase III trials.
Current ongoing research includes preclinical models of therapy with biological agents, early studies with gene therapy vectors and tyrosine kinase inhibitors, and leading phase II and phase III trials with novel agents. He has published widely on the molecular biology, early detection, and treatment of
gastrointestinal malignancies.
Dr. Hecht attended medical school at Eastern Virginia Medical School. He completed his internal medicine residency at Northwestern and fellowships in gastroenterology research at the University of Chicago, and in gastroenterology and medical oncology at UCLA.
Kimberly Halla, MSN, FNP-C, is a patient-oriented Family Nurse Practitioner at Arizona Oncology Associates PC in Scottsdale, Arizona. She received her MSN degree with honors from Grand Canyon University in Phoenix, Arizona in 2015. Ms. Halla is an expert in the field of oncology and medical surgical care. At Arizona Oncology Associates PC, she is responsible for the continued assessment and interventions of all active chemotherapy patients from initiation of treatment through survivorship, the development of individualized survivorship programs in compliance with the Oncology Care Model, and their continued surveillance and assessment as per the National Comprehensive Cancer Network for a
large Gynecologic Oncology practice.
Ms. Halla has been caring for oncology patients in multiple roles since 2008. She has a background in education and truly believes that this is at the heart of what she does. She continues to participate in
the ongoing education of her peers and colleagues to include caring for the gyn/onc patient after surgery and during chemotherapy and their survivorship. As a subinvestigator on multiple research trials, she has been able to see firsthand new and exciting treatment options that continue to improve the lives of patients.
Clara Beaver, DNP, RN, AOCNS, ACNS, BC has been an
oncology nurse for over 25 years. Ms. Beaver has been a clinical
nurse specialist at Karmanos for over 19 years. She earned her
DNP from Grand Valley State University in 2023. She is also very
active with ONS and ONCC, just coming off the ONCC board after
6 years of service.
Learning Objectives:
- Summarize the impact of AEs associated with ADC use on the health-related
quality of life (HRQoL) of patients with HER2-neg MBC
- Differentiate patients with HER2-neg MBC who are at risk of higher-grade AEs
when receiving ADCs
- Select optimal approaches to the management of AEs associated with ADC use
by patients with HER2-neg MBC
Michael Mauro is Attending Physician, Professor of Medicine, Director, Chronic Myeloid Leukemia Program, and Member, Memorial Sloan Kettering Cancer Center, in New York City. After receiving his BS and MD from Dartmouth College and Dartmouth Medical School in New Hampshire, he completed both residency and fellowship training at the New York-Presbyterian Hospital/Weill Cornell Medical College in Manhattan. Before joining Memorial Sloan Kettering, Dr. Mauro was on the faculty of Oregon Health and Sciences University for 13
years, where he directed the CML clinical trial program and was involved in the early development and sentinel clinical studies of ABL kinase inhibitors for CML. Dr. Mauro’s clinical expertise is in treating patients with chronic myeloid leukemia (CML) as well as other myeloproliferative disorders, including myelofibrosis, polycythemia, and thrombocytosis as well as less common conditions such as eosinophilic and mast cell disorders. His research interests are development of novel agents for CML, increasing the option of treatment free remission
(TFR) / functional cure in CML and identification and management of tyrosine kinase inhibitor related adverse events, specifically cardiovascular events. He holds positions on the boards of the International CML Foundation, the MAX Foundation, and the Leukemia and Lymphoma Society.
Teresa Knoop, MSN, RN, AOCN-Emeritus (emerita Vanderbilt)
Copyright 2024 GLAONS All rights reserved.